pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 6·1 min read
save

Health AI progress limited by bad data, newsletter notes

May 6, 2026·read at STAT ↗Neutral

The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine.

The author explains that many existing datasets contain errors, biases, and gaps, which can lead to models that perform poorly or produce misleading results when applied to real-world clinical settings.

To make AI reliable, the piece calls for better data collection standards, transparent reporting, and collaboration among clinicians, researchers, and technology developers.

The newsletter also mentions upcoming events where these issues will be discussed, underscoring the growing attention to data integrity in health AI.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: When the path to good AI is littered with bad data”

read at STAT ↗
448 words · retrieved May 6
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH2Boundless Bio, Inc.InSilico Medicine
topics
Ophthalmology

related stories

  • Jun 13Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73STAT
  • May 9Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national newsSTAT
  • Sep 25After COVID, biomanufacturing tackles preparedness and commercialization challengesBioSpace
  • Sep 24Merck reveals study success, and possible safety worries, for eye drug hopefulBioPharma Dive
  • Sep 20Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapyFierce Biotech